CALL US TODAY:
(305) 274-0221

Baricitinib Beneficial in Two Phase 3 Atopic Dermatitis Trials

08

  • Feb

  • 2019

images images Latest News images 0 Comments
Baricitinib Beneficial in Two Phase 3 Atopic Dermatitis Trials

Baricitinib, a Janus kinase inhibitor, is currently approved under the brand name Olumiant for the treatment of moderately-to-severely active rheumatoid arthritis.

« Previous
Next »

Follow Us

  • LinkedIn
  • YouTube

Patient Portal

Pay Your Bill Online!

© 2024 Judith Crowell, MD and Associates


7800 SW 87th Avenue | Suite C-300 | Miami, Florida 33173

Designed By Emrah Interactive